Sugi Predict

Sugi Predict / Compounds / SCHEMBL905415

SCHEMBL905415

SCHEMBL905415

COC(=O)CCCCCCCCCCCCCCC(=O)O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 8/20 0.86
▸ ALDH1A1 P00352 4/20 0.60
▸ LMNA P02545 3/20 0.60
▸ NFKB1 P19838 1/20 0.60
▸ PMP22 Q01453 1/20 0.60
▸ GPR84 Q9NQS5 7/20 0.54
▸ PPARG P37231 6/20 0.54
▸ PPARD Q03181 6/20 0.54
▸ PPARA Q07869 6/20 0.54
▸ HDAC11 Q96DB2 5/20 0.54
▸ TLR2 O60603 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ FABP4 P15090 2/20 0.54
▸ PTPN1 P18031 2/20 0.54
▸ SLC22A6 Q4U2R8 1/20 0.54
▸ SLC22A8 Q8TCC7 1/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ ESR1 P03372 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ PDE4A P27815 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3505308 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3503428 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3504394 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3502474 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3504014 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
Sebacic Acid SCHEMBL10962129 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
Sebacic Acid SCHEMBL10956921 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
Adipic Acid SCHEMBL10792220 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3504444 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22
SCHEMBL3503109 1.00 TSHR (0.86) TSHRALDH1A1LMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139257-A1 PLIN1 RNAi INTERFERENCE AGENTS ELI LILLY AND CO (US) 2026-05-21 — — US disclosed
WO-2025108237-A1 LIPID COMPOUND, NUCLEIC ACID CONJUGATE AND USE THEREOF 施能康生物科技有限公司 2025-05-30 — — WO disclosed
CN-120025369-A Lipid compound, nucleic acid conjugate and application thereof 施能康生物科技有限公司 2025-05-23 — — CN disclosed
CN-119709746-A Extrahepatic delivery 阿尔尼拉姆医药品有限公司 2025-03-28 — — CN disclosed
CN-119546570-A Memantine derivatives, pharmaceutical compositions thereof and uses thereof 广州市恒诺康医药科技有限公司 2025-02-28 — — CN disclosed
CN-114945669-B Extrahepatic delivery 阿尔尼拉姆医药品有限公司 2025-01-10 — — CN disclosed
WO-2024012565-A1 MEMANTINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 广州市恒诺康医药科技有限公司 2024-01-18 — — WO disclosed
US-20230304002-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES BANK OF AMERICA, N.A. 2023-09-28 — — US disclosed
US-20230304002-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES BANK OF AMERICA, N.A. 2023-09-28 — — US disclosed
US-20230272382-A1 COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES BANK OF AMERICA, N.A. 2023-08-31 — — US disclosed
US-20100009899-A1 Novel Insulin Derivatives NOVO NORDISK A/S (DK) 2010-01-14 — — US disclosed
US-7615532-B2 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DE) 2009-11-10 — — US disclosed
EP-2107069-A2 Novel insulin derivatives NOVO NORDISK A/S (DK) 2009-10-07 — — EP disclosed
US-20060183668-A1 Antidiabetic agents; insulin derivatives which are naturally occurring insulins or analogues thereof which have a side chain attached either to the alpha-amino group of the N-terminal amino acid residue of the B chain or to epsilon-amino group of a Lys residue present in the B chain of parent insulin NOVO NORDISK A/S (DK) 2006-08-17 — — US disclosed
EP-1660531-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2006-05-31 — — EP disclosed
WO-2005012347-A2 NOVEL INSULIN DERIVATIVES NOVO NORDISK A/S (DK) 2005-02-10 — — WO disclosed
US-5391564-A E.g., rhizoxin-13-yl 3-methylthiopropionate; anticarcinogenic agents SANKYO COMPANY, LIMITED (JP) 1995-02-21 — — US disclosed
US-5352689-A Rhizoxin derivatives and their use as anti-tumor agents SANKYO COMPANY, LIMITED (JP) 1994-10-04 — — US disclosed
EP-0350315-B1 RHIZOXIN DERIVATES AND THEIR USE AS ANTI-TUMOR AGENTS SANKYO COMPANY LIMITED (JP) 1993-06-16 — — EP disclosed
EP-0350315-A1 Rhizoxin derivates and their use as anti-tumor agents SANKYO COMPANY LIMITED (JP) 1990-01-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139257-A1 PLIN1 RNAi INTERFERENCE AGENTS PLIN1, PLIN3, PLIN5 TSHR 3291/4885ALDH1A1 3231/4885LMNA 70/4885
US-20230304002-A1 TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES TTR, MTPN, CRYAA TSHR 510/4885ALDH1A1 1700/4885LMNA 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.